EGFR and lung carcinoma: Well-characterized examples include the BCR-ABL translocation in Philadelphia chromosome-positive leukemias, which confers sensitivity to the ABL tyrosine kinase inhibitor imatinib [18–20], as well as epidermal growth factor receptor (EGFR)-mutant lung cancers, which are sensitive to EGFR inhibition.